|
US2020140923A1
|
|
Methods of rna amplification
|
|
KR20180064544A
|
|
Method for detecting nucleic acid size of repeating subsequence
|
|
AU2016297631A1
|
|
Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating A/T-rich segments
|
|
US2018163261A1
|
|
Methods and apparatuses for improving mutation assessment accuracy
|
|
AU2014202177A1
|
|
Methods and compositions involving mirna and mirna inhibitor molecules
|
|
US2014024035A1
|
|
Comprehensive FMR1 genotyping
|
|
US2014100124A1
|
|
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
|
US2013142728A1
|
|
Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
|
|
WO2013063519A1
|
|
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
|
AU2012244061A1
|
|
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
WO2013040251A2
|
|
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
|
AU2011253959A1
|
|
Methods and compositions involving MicroRNA
|
|
EP2640851A2
|
|
Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
|
|
BR112013010585A2
|
|
method of characterizing a fmr1 locus or a frm2 locus in a DNA sample and a method of analyzing a fmr1 locus or an fmr2 locus in a human DNA sample
|
|
WO2011025919A1
|
|
Mirna biomarkers of lung disease
|
|
CA2762986A1
|
|
Mirna biomarkers of prostate disease
|
|
CN102449171A
|
|
Pcr methods for characterizing the 5' untranslated region of the fmr1 and fmr2 genes
|
|
KR20110120923A
|
|
Method of amplification of gc-rich dna templates
|
|
WO2009149418A2
|
|
Compositions for the in vivo delivery of rnai agents
|
|
EP2990487A1
|
|
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
